LNP Litigation Settlement with Moderna

March 3, 2026

roivant



Forward-Looking Statements

This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. All statements other than statements of historical facts contained in this presentation, including statements regarding potential future contingent payments pursuant to the Settlement Agreement with Moderna, our future results of operations and financial position, business strategy, potential uses of cash and capital allocation, research and development plans, profitability, the anticipated timing, costs, design, conduct and results of our ongoing and planned preclinical studies and clinical trials for our products and product candidates, and any commercial potential of our products and product candidates are forward-looking statements.

These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements.

These forward-looking statements may be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the sections captioned “Risk Factors” and “Forward-Looking Statements” of our filings with the U.S. Securities and Exchange Commission, available at www.sec.gov and investor.roivant.com. We operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Moderna Patent Litigation Timeline: Years in the Making



Settlement Validates the Seminal Work of Genevant/Arbutus Inventors:
Ian MacLachlan, Ed Yaworski, Lloyd Jeffs, Kieu Lam, Lorne Palmer and Cory Giesbrecht

Moderna Settlement Will Be the Largest Disclosed Biopharma Patent Settlement in History, If $1.3BN Contingent Payment Is Realized

$950M

Upfront payment due July 2026

+

$1.3BN

Contingent payment upon an appellate ruling that Section 1498 does not bar Genevant's and Arbutus' claims against Moderna for patent infringement[1]

=

$2.25BN

Aggregate settlement value

Covers Moderna's ~33% Global Market Share[2] of COVID-mRNA Sales; Litigation Continues with Pfizer/BioNTech

roivant

1. Contingent payment refundable to Moderna if appellate ruling is overturned in Moderna's favor. For more information about the terms and conditions of the contingent payment, please refer to Roivant's Current Report on Form 8-K filed with the SEC on March 3, 2026.
2. Measured cumulatively through December 31, 2025. Moderna market share Include sales that Moderna contends are subject to Section 1498

Key Terms and Conditions

Settlement holds Moderna accountable for infringement

Upfront Payment

$950M

To be received by Genevant/Arbutus in July 2026

IP License

Moderna receives global non-exclusive license to LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Genevant/Arbutus patents and Moderna products

Contingent Payment

$1.3BN

Contingent payment upon an appellate ruling that Section 1498 does not bar Genevant's and Arbutus' claims against Moderna for patent infringement[1]

- Moderna retains right to appeal solely on question of whether Moderna or U.S. taxpayers are liable for Moderna's infringement for sales made under one of its government contracts
- Moderna to pay pro rata portion of $1.3BN on a partial affirmance
- Payment would be returned to Moderna if judgment is reversed in a final non-appealable judgment
- Genevant/Arbutus are entitled to pursue claims in the Court of Federal Claims for any doses ultimately deemed subject to Section 1498
- Agreement includes robust credit protections on $1.3BN contingent payment

roivant

1. For more information about the terms and conditions of the contingent payment, please refer to Roivant's Current Report on Form 8-K filed with the SEC on March 3, 2026.

Settlement Validates the Inventors' Patents, Provides Clarity and Reduces Appellate Risk

Parties involved	Year of Verdict	Amount of Verdict	Year of Final Resolution	Amount of Final Resolution	Comments
Genevant/Arbutus v. Moderna			***2026***	***$2.25BN****	***Parties agreed to a settlement in which Moderna pays Genevant and Arbutus an upfront payment of $925M and a contingent payment of $1.3BN[1]***
Idenix v. Gilead	**2016**	**$2.54BN**	**2018**	**$0**	**Gilead's JMOL granted on enablement, verdict entirely vacated**
VLSI v. Intel	2021	$2.18BN	2023	$0	Fed Circuit reversed infringement finding for one patent, reversed and remanded as to damages for second patent
Pfizer v. Teva and Sun Pharma	**2013**	**$2.15BN**	**2013**	**$2.15BN**	**Settlement, Teva to pay $1.6BN and Sun Pharma to pay $550M**
Centocor v. Abbott	**2009**	**$1.672BN**	**2011**	**$0**	**Verdict reversed on failure to satisfy written description requirement; $1.672BN award entirely vacated**
Alcatel-Lucent v Microsoft	2007	$1.53BN	2008	$0	Appellate court dismissed case on two grounds (lack of standing to sue and failure to prove IP was used by Microsoft); verdict entirely vacated
Litton v. Honeywell	1993	$1.2BN	2002	Not confirmed	District court granted summary judgment and JMOL for noninfringement on remand; verdict was effectively vacated
Carnegie Mellon University v. Marvell	2012	$1.17BN	2016	$750M	Settlement for $750M
Apple v. Samsung	2012	$1.049BN	2018	Undisclosed	Parties agrees to an undisclosed settlement
Monsanto v. DuPont	2012	$1.0BN	2013	$1.75BN	Parties entered into cross-licensing agreement with DuPont paying $1.75BN in royalties
Polaroid v. Kodak	1991	$925M	1991	$925M	Kodak paid full $925M award

Italics indicates representative values for current settlement with Moderna.
Bold blue font indicates biopharma cases.

1. Contingent payment refundable to Moderna if appellate ruling is overturned in Moderna's favor. For more information about the terms and conditions of the contingent payment, please refer to Roivant's Current Report on Form 8-K filed with the SEC on March 3, 2026.

Roivant's Share of Proceeds From Settlement Supports Advancement of Current Priorities and Accelerates Capital Return to Shareholders

$950M

Settlement proceeds to be paid July 2026

10-15%

Effective tax rate expected on ROIV proceeds from this payment

60-70%[1]

ROIV (and subsidiaries) economic share of settlement

roivant

1. Range represents economic share based on ROIV's basic to diluted share of proceeds.

Today Marks Major Progress for LNP Litigation, But It Is Not the End

Moderna Settlement

Reached aggregate $2.25BN settlement with Moderna on the eve of trial

Settlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity

Contingent payment due on appellate ruling that Section 1498 does not bar Genevant's and Arbutus' claims against Moderna for patent infringement; Moderna retains rights to appeal solely on question of whether Moderna or U.S. taxpayers are liable for Moderna's infringement under first COVID-19 government contract[1]

Section 1498 issue has already been decided in Genevant/Arbutus' favor 3 times by 2 different judges

Pfizer/BioNTech

Litigation is ongoing in the U.S. following favorable Markman ruling in September 2025

roivant

1. Contingent payment refundable to Moderna if appellate ruling is overturned in Moderna's favor. For more information about the terms and conditions of the contingent payment, please refer to Roivant's Current Report on Form 8-K filed with the SEC on March 3, 2026.

As a Reminder, Moderna COVID-19 Vaccine Sales Account for <1/3rd of All Global COVID-19 Vaccine Sales



- Total SpikeVax sales account for ~1/3 of mRNA vaccine sales to date; Comirnaty sales account for remaining ~2/3
- U.S. SpikeVax sales make up ~10% of global COVID-mRNA vaccine sales to date
- Genevant/ABUS continue to pursue recovery against Pfizer and BioNTech

roivant

Sales as of 12/31/2025
Data and sales calculated from Evaluate Pharma and company docs from MRNA, PFE, and BNTX
MRNA: Moderna; PFE: Pfizer; BNTX: BioNTech

Brepocitinib Update



roivant

FDA Assigns PDUFA Date in the Third Quarter of 2026, With Launch of Brepocitinib in the U.S. Expected By the End of September 2026

FDA Accepted NDA for Brepocitinib in Dermatomyositis

NDA Granted Priority Review, Supported by Positive Phase 3 VALOR Results

PDUFA Target Action Date in the Third Quarter of Calendar Year 2026

U.S. Launch of Brepocitinib in DM Expected by the End of September 2026



roivant

Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All references are to calendar years
NDA: New Drug Application
PDUFA: Prescription Drug User Fee Act

High-Value Pipeline, Delivering Series of Near-Term Catalysts



roivant

Note: All drugs are investigational and subject to regulatory approvals. All catalyst timings are approximate, based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All references are to calendar years

Thank you.



roivant